Antibiotics: What's new?

Cutis

Volumn 73, Issue 5 SUPPL., 2004, Pages 10-14

  LaRosa, Steven P ^a,b   Tomecki, Kenneth J ^a,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFAZOLIN; CIPROFLOXACIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DICLOXACILLIN; ENOXACIN; GATIFLOXACIN; LINEZOLID; LOMEFLOXACIN; MACROLIDE; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; OXACILLIN; OXAZOLIDINEDIONE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SEROTONIN AGONIST; STREPTOGRAMIN; VANCOMYCIN;

BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONFERENCE PAPER; CONFUSION; DELIRIUM; DIAPHORESIS; DIARRHEA; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DRUG STRUCTURE; HUMAN; HYPERPYREXIA; NAUSEA; NONVERBAL COMMUNICATION; RESTLESSNESS; SEROTONIN SYNDROME; SKIN INFECTION; TREMOR; VOMITING;

ANTI-BACTERIAL AGENTS; FLUOROQUINOLONES; HUMANS; OXAZOLIDINONES; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; STREPTOGRAMINS;

EID: 2642542286     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Guay DR. Treatment of bacterial skin and skin structure infections. Expert Opin Pharmacother. 2003;4:1259-1275.
2. Quinupristin/dalfopristin. Med Lett Drugs Ther. 1999;41:109-110.
3. Koul A, Vitullo J, Reyes G, et al. Effects of voriconazole on Candida glabrata in vitro. J Antimicrob Chemother. 1999;44:109-112.
4. Winston DJ, Emmanouilides C, Kroeber A, et al. Quinupristin/dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium. Clin Infect Dis. 2000;30:790-797.
5. Drew RH, Perfect JR, Srinath L, et al, for the Synercid Emergency-Use Study Group. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. J Antimicrob Chemother. 2000;46:775-784.
6. Nichols RL, Graham DR, Barriere SL, et al, for the Synercid Skin and Skin Structure Infection Group. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. J Antimicrob Chemother. 1999;44:263-273.
7. Fagon J, Patrick H, Haas DW, et al, for the Nosocomial Pneumonia Group. Treatment of gram-positive nosocomial pneumonia, prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Am J Respir Crit Care Med. 2000;161:753-762.
8. Moellering RC Jr. Linezolid: the first oxazolidinones antimicrobial. Ann Intern Med. 2003;138:135-142.
9. Linezolid (Zyvox)[news]. Med Lett Drugs Ther. 2000;42:45-46.
10. Stevens DL, Smith LG, Bruss JB, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2000;44:3408-3413.
11. Rubinstein E, Cammarata S, Oliphant T, et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis. 2001;32:402-412.
12. Centers for Disease Control. Fact sheet: quinolones and the clinical laboratory. Available at: http://www.cdc.gov. Accessed December 18, 2003.
13. Fish DN, North DS. Gatifloxacin, an advanced 8-methoxy fluoroquinolone. Pharmacotherapy. 2001;21:35-39.
14. Saravolatz LD, Leggett J. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones. Clin Infect Dis. 2003;37:1210-1215.
15. Brown-Elliott BA, Wallace RJ Jr, Crist CJ, et al. Comparison of in vitro activities of gatifloxacin and ciprofloxacin against four taxa of rapidly growing mycobacteria. Antimicrob Agents Chemother. 2002;46:3283-3285.
16. Tarshis GA, Miskin BM, Jones TM, et al. Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study. Antimicrob Agents Chemother. 2001;45:2358-2362.